pioglitazone has been researched along with Nerve Degeneration in 8 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "X-linked adrenoleukodystrophy is a neurometabolic disorder caused by inactivation of the peroxisomal ABCD1 transporter of very long-chain fatty acids." | 5.39 | Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. ( Aubourg, P; Beal, MF; Calingasan, NY; Dumont, M; Ferrer, I; Fourcade, S; Galea, E; Galino, J; Martínez, JJ; Morató, L; Naudí, A; Pamplona, R; Portero-Otín, M; Pujol, A; Ruiz, M; Starkov, AA, 2013) |
| "X-linked adrenoleukodystrophy is a neurometabolic disorder caused by inactivation of the peroxisomal ABCD1 transporter of very long-chain fatty acids." | 1.39 | Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. ( Aubourg, P; Beal, MF; Calingasan, NY; Dumont, M; Ferrer, I; Fourcade, S; Galea, E; Galino, J; Martínez, JJ; Morató, L; Naudí, A; Pamplona, R; Portero-Otín, M; Pujol, A; Ruiz, M; Starkov, AA, 2013) |
| "Pioglitazone treatment reduced the infarct size and improved neurological functions." | 1.35 | Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Stöck, I; Zhao, Y, 2008) |
| "Pretreatment with pioglitazone completely prevented these effects of MPTP." | 1.35 | The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. ( Chapman, H; Crook, B; Hows, ME; Medhurst, AD; Quinn, LP; Upton, N; Vidgeon-Hart, M; Virley, DJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morató, L | 1 |
| Galino, J | 1 |
| Ruiz, M | 1 |
| Calingasan, NY | 1 |
| Starkov, AA | 1 |
| Dumont, M | 1 |
| Naudí, A | 1 |
| Martínez, JJ | 1 |
| Aubourg, P | 1 |
| Portero-Otín, M | 1 |
| Pamplona, R | 1 |
| Galea, E | 1 |
| Beal, MF | 1 |
| Ferrer, I | 1 |
| Fourcade, S | 1 |
| Pujol, A | 1 |
| Dief, AE | 1 |
| Kamha, ES | 1 |
| Baraka, AM | 1 |
| Elshorbagy, AK | 1 |
| Yu, SJ | 1 |
| Reiner, D | 1 |
| Shen, H | 1 |
| Wu, KJ | 1 |
| Liu, QR | 1 |
| Wang, Y | 1 |
| Liu, M | 2 |
| Bachstetter, AD | 1 |
| Cass, WA | 2 |
| Lifshitz, J | 1 |
| Bing, G | 2 |
| Patzer, A | 1 |
| Zhao, Y | 1 |
| Stöck, I | 1 |
| Gohlke, P | 1 |
| Herdegen, T | 1 |
| Culman, J | 1 |
| Schütz, B | 1 |
| Reimann, J | 1 |
| Dumitrescu-Ozimek, L | 1 |
| Kappes-Horn, K | 1 |
| Landreth, GE | 1 |
| Schürmann, B | 1 |
| Zimmer, A | 1 |
| Heneka, MT | 1 |
| Hunter, RL | 1 |
| Dragicevic, N | 1 |
| Seifert, K | 1 |
| Choi, DY | 1 |
| Kim, HC | 1 |
| Sullivan, PG | 1 |
| Quinn, LP | 1 |
| Crook, B | 1 |
| Hows, ME | 1 |
| Vidgeon-Hart, M | 1 |
| Chapman, H | 1 |
| Upton, N | 1 |
| Medhurst, AD | 1 |
| Virley, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)[NCT00690118] | Phase 2 | 219 participants (Actual) | Interventional | 2008-05-31 | Terminated (stopped due to The interim analysis showed no tendency in favour of the verum group. Therefore it was decided to stop the study prematurely.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for pioglitazone and Nerve Degeneration
| Article | Year |
|---|---|
Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy.
Topics: Adrenoleukodystrophy; Animals; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP-Binding | 2013 |
Monosodium glutamate neurotoxicity increases beta amyloid in the rat hippocampus: a potential role for cyclic AMP protein kinase.
Topics: AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animals; Behavior, Animal; Fas Ligand Protein; | 2014 |
Time-Dependent Protection of CB2 Receptor Agonist in Stroke.
Topics: Animals; Behavior, Animal; Brain Ischemia; Calcium-Binding Proteins; Cannabinoid Receptor Agonists; | 2015 |
Pioglitazone Attenuates Neuroinflammation and Promotes Dopaminergic Neuronal Survival in the Nigrostriatal System of Rats after Diffuse Brain Injury.
Topics: Animals; Brain Injuries, Diffuse; Cell Survival; Dopaminergic Neurons; Inflammation; Inflammation Me | 2017 |
Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Ence | 2008 |
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Animals; Humans; Hypoglycemic Agents; Male; Mic | 2005 |
Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Topics: Animals; Celecoxib; Cell Death; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Dopamine; In Vitro Tec | 2007 |
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Hypoglycemic | 2008 |